期刊文献+

静脉滴注氟康唑致尖端扭转型室性心动过速

Torsades de pointes after receiving anⅣinfusion of fluconazole
原文传递
导出
摘要 1例81岁女性患者因肺部真菌感染静脉滴注氟康唑200 mg,1次/d。输注10 min后患者心电图显示频发室性早搏,随即静脉注射利多卡因及静脉滴注氯化钾,10 min后心电图显示尖端扭转型室性心动过速,继而出现心室颤动。立即给予胸外按压和电除颤、并静脉给予利多卡因、硫酸镁及门冬氨酸钾镁等治疗。次日输注氟康唑注射液5 min后再次发生尖端扭转型室性心动过速和心室颤动。停用氟康唑注射液,改用伊曲康唑注射液抗真菌治疗。此后未再出现尖端扭转型室性心动过速和心室颤动。 An 81-year-old woman with pulmonary fungal infection received an Ⅳ infusion of fluconazole 200 mg once daily.Ten minutes after infusion started,the patient's electrocardiogram showed frequent ventricular premature beats,and then an Ⅳ push of lidocaine and an Ⅳ infusion of potassium chloride were given immediately.Ten minutes later,the patient's electrocardiogram showed torsades de pointes and ventricular fibrillation.She was immediately treated with chest compression and defibrillation,followed by Ⅳ lidocaine,Ⅳ magnesium sulfate and Ⅳ potassium magnesium aspirate.The next day,torsades de pointes and ventricular fibrillation occurred again 5 minutes after an Ⅳ infusion of fluconazole.Fluconazole was withdrawn immediately and her therapy was changed to itraconazole injection for antifungal therapy.After this change,her torsades de pointes and ventricular fibrillation did not recur.
作者 张寒钰
出处 《药物不良反应杂志》 CSCD 2013年第1期42-43,共2页 Adverse Drug Reactions Journal
关键词 氟康唑 尖端扭转型室性心动过速 心室颤动 Fluconazole Torsades de pointes Ventricular fibrillation
  • 相关文献

参考文献6

二级参考文献39

  • 1程树军,单文俊,丁玉庆.静滴青霉素致哮喘1例[J].医学理论与实践,2005,18(2):130-130. 被引量:1
  • 2江腊梅,张敏.抗菌药物的心脏毒性[J].中国药物警戒,2006,3(1):18-20. 被引量:7
  • 3王睿.阿霉素诱导心脏毒性保护药物研究进展[J].黑龙江医药科学,2006,29(5):86-86. 被引量:4
  • 4黄文起,刘宽智.局麻药物对神经及心血管的毒性[J].广东医学,2006,27(11):1597-1599. 被引量:10
  • 5Gupta AK, Chwetzoff E, Del Rosso J, et al.Hepatic safety of itraconazole. J Cutan Med Surg, 2002, 6: 210-213.
  • 6Gupta AK, Shear NH. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol, 1999, 38Suppl 2: 40-52.
  • 7Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol, 1997, 133: 1213-1219.
  • 8Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol, 2000, 41:42-45.
  • 9Callen JP, Hughes AP, Kulp-Shorten C. et al. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol, 2001, 137:1196-1198.
  • 10Stricker BH, Van Riemsdijk MM, Sturkenboom MC, et al. Taste loss to terbinafine: a case-control study of potential risk factors.Br J Clin Pharmacol, 1996, 42: 313-318.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部